Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Multitarget Therapeutic Strategies for Alzheimer’s Disease: Review on Emerging Target Combinations
Samuele Maramai, Mohamed Benchekroun, Moustafa T. Gabr, et al.
BioMed Research International (2020) Vol. 2020, pp. 1-27
Open Access | Times Cited: 88

Showing 1-25 of 88 citing articles:

Recent advances in Alzheimer’s disease: Mechanisms, clinical trials and new drug development strategies
Jifa Zhang, Yinglu Zhang, Jiaxing Wang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 80
Mitochondrial dysfunctions, oxidative stress and neuroinflammation as therapeutic targets for neurodegenerative diseases: An update on current advances and impediments
Muneeb U. Rehman, Nouroz Sehar, Nawab John Dar, et al.
Neuroscience & Biobehavioral Reviews (2022) Vol. 144, pp. 104961-104961
Closed Access | Times Cited: 74
Advancements in the development of multi-target directed ligands for the treatment of Alzheimer’s disease
Naveen Kumar, Vijay Kumar, Piyush Anand, et al.
Bioorganic & Medicinal Chemistry (2022) Vol. 61, pp. 116742-116742
Closed Access | Times Cited: 66
The promise of microRNA-based therapies in Alzheimer’s disease: challenges and perspectives
Hannah Walgrave, Lujia Zhou, Bart De Strooper, et al.
Molecular Neurodegeneration (2021) Vol. 16, Iss. 1
Open Access | Times Cited: 86
Tau Oligomers Neurotoxicity
Grażyna Niewiadomska, Wiktor Niewiadomski, Marta Steczkowska, et al.
Life (2021) Vol. 11, Iss. 1, pp. 28-28
Open Access | Times Cited: 85
Superoxide dismutase as multipotent therapeutic antioxidant enzyme: Role in human diseases
Priyanka Saxena, Kanagarethinam Selvaraj, Sunil Kumar Khare, et al.
Biotechnology Letters (2021) Vol. 44, Iss. 1, pp. 1-22
Closed Access | Times Cited: 73
Green Tea Epigallocatechin-3-gallate (EGCG) Targeting Protein Misfolding in Drug Discovery for Neurodegenerative Diseases
Priscila Baltazar Gonçalves, Ana Carolina Rennó Sodero, Yraima Cordeiro
Biomolecules (2021) Vol. 11, Iss. 5, pp. 767-767
Open Access | Times Cited: 70
β-Carboline as a Privileged Scaffold for Multitarget Strategies in Alzheimer’s Disease Therapy
Aurélien Beato, Anthonin Gori, Benjamin Boucherle, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 3, pp. 1392-1422
Open Access | Times Cited: 55
Disaccharide trehalose in experimental therapies for neurodegenerative disorders: Molecular targets and translational potential
А. Б. Пупышев, T. P. Klyushnik, Anna A. Akopyan, et al.
Pharmacological Research (2022) Vol. 183, pp. 106373-106373
Closed Access | Times Cited: 45
Novel benzothiazole derivatives as multitargeted-directed ligands for the treatment of Alzheimer’s disease
Donia E. Hafez, Mariam Dubiel, Gabriella La Spada, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2023) Vol. 38, Iss. 1
Open Access | Times Cited: 27
High-Throughput Screening and Molecular Dynamics Simulation of Natural Product-like Compounds against Alzheimer’s Disease through Multitarget Approach
Danish Iqbal, Md Tabish Rehman, Abdulaziz Bin Dukhyil, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 9, pp. 937-937
Open Access | Times Cited: 44
C-Phycocyanin-derived Phycocyanobilin as a Potential Nutraceutical Approach for Major Neurodegenerative Disorders and COVID-19- induced Damage to the Nervous System
Giselle Pentón‐Rol, Javier Marín‐Prida, Mark F. McCarty
Current Neuropharmacology (2021) Vol. 19, Iss. 12, pp. 2250-2275
Open Access | Times Cited: 41
Unveiling the Multitarget Anti-Alzheimer Drug Discovery Landscape: A Bibliometric Analysis
Anna Sampietro, F. Javier Pérez-Areales, Paula Felippe Martinez, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 5, pp. 545-545
Open Access | Times Cited: 32
Multipharmacophore strategy in medicinal chemistry for the design of drugs for the treatment of Alzheimer’s and some other neurodegenerative diseases
С. О. Бачурин, А. Yu. Aksinenko, Галина Ф. Махаева, et al.
Russian Chemical Bulletin (2023) Vol. 72, Iss. 1, pp. 130-147
Closed Access | Times Cited: 16
Synthesis and evaluation of multitarget new 2‐aminothiazole derivatives as potential anti‐Alzheimer's agents
Merve Bardakkaya, Burcu Kılıç, Rahşan Ilıkçı Saǧkan, et al.
Archiv der Pharmazie (2023) Vol. 356, Iss. 8
Open Access | Times Cited: 16
Light-mediated Activation/Deactivation Control and in vitro ADMETox Profiling of a Donepezil-like Dual AChE/MAO-B Inhibitor
Federica Poggialini, Paolo Governa, Chiara Vagaggini, et al.
European Journal of Pharmaceutical Sciences (2025), pp. 107066-107066
Open Access
A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease
Karolina Maciejewska, Kamila Czarnecka, Paweł Szymański
Pharmacological Reports (2021) Vol. 73, Iss. 6, pp. 1565-1581
Open Access | Times Cited: 37
Synthesis, kinetic evaluation and molecular docking studies of donepezil-based acetylcholinesterase inhibitors
Makar Makarian, Michael Gonzalez, Stephanie M. Salvador, et al.
Journal of Molecular Structure (2021) Vol. 1247, pp. 131425-131425
Open Access | Times Cited: 36
Lipoic acid. Kinetics and pluripotent biological properties and derivatives
Panagiotis Theodosis‐Nobelos, Georgios Papagiouvannis, Paraskevi Tziona, et al.
Molecular Biology Reports (2021) Vol. 48, Iss. 9, pp. 6539-6550
Closed Access | Times Cited: 34
The recent development of donepezil structure-based hybrids as potential multifunctional anti-Alzheimer's agents: highlights from 2010 to 2020
Rzgar Tawfeeq Kareem, Fahimeh Abedinifar, Evan Abdolkareem Mahmood, et al.
RSC Advances (2021) Vol. 11, Iss. 49, pp. 30781-30797
Open Access | Times Cited: 34
Inhibition of phosphodiesterase: A novel therapeutic target for the treatment of mild cognitive impairment and Alzheimer’s disease
Jianwen Sheng, Shanjin Zhang, Lule Wu, et al.
Frontiers in Aging Neuroscience (2022) Vol. 14
Open Access | Times Cited: 23
Design, Synthesis, and Pharmacological Evaluation of Embelin–Aryl/alkyl Amine Hybrids as Orally Bioavailable Blood–Brain Barrier Permeable Multitargeted Agents with Therapeutic Potential in Alzheimer’s Disease: Discovery of SB-1448
Vijay K. Nuthakki, Sushil Choudhary, Chilakala Nagarjuna Reddy, et al.
ACS Chemical Neuroscience (2023) Vol. 14, Iss. 6, pp. 1193-1219
Closed Access | Times Cited: 12
Design and synthesis of multi-target directed 1,2,3-triazole-dimethylaminoacryloyl-chromenone derivatives with potential use in Alzheimer's disease
Hajar Karimi Askarani, Aida Iraji, Arezoo Rastegari, et al.
BMC Chemistry (2020) Vol. 14, Iss. 1
Open Access | Times Cited: 34
Zinc-dependent deacetylases (HDACs) as potential targets for treating Alzheimer’s disease
Yan Li, Shuxian Lin, Zhicheng Gu, et al.
Bioorganic & Medicinal Chemistry Letters (2022) Vol. 76, pp. 129015-129015
Closed Access | Times Cited: 20
On the relationships between epilepsy, sleep, and Alzheimer’s disease: A narrative review
Julie M. Hanke, Kaspar Schindler, Andrea Seiler
Epilepsy & Behavior (2022) Vol. 129, pp. 108609-108609
Open Access | Times Cited: 19
Page 1 - Next Page

Scroll to top